National clinical trials offered at Massey utilize precision medicine aimed at improving treatment of early-stage lung cancer
VCU Massey Cancer Center is currently offering clinical trials for patients with early-stage lung cancer that utilize cutting-edge precision medicine techniques with the aim of improving treatment. This group of three integrated national clinical trials known as ALCHEMIST – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials – use next-generation sequencing to identify patients with early-stage lung cancer whose tumors harbor specific and uncommon changes in two particular genes, epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK), thought to drive cancer growth.
Massey research leads to multi-institutional phase 1 clinical trial for relapsed/refractory aggressive lymphomas
Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., is the co-principal investigator (PI) on a National Comprehensive Cancer Network (NCCN) grant funding a phase 1 clinical trial testing the drugs volasertib and belinostat in patients with relapsed and refractory aggressive B-cell and T-cell lymphomas. The $453,852 award will help implement the clinical trial at Massey, Yale Comprehensive Cancer Center and Johns Hopkins’ Sidney Kimmel Comprehensive Cancer Center.
International study co-led by Massey researcher finds ovarian suppression reduces breast cancer recurrence for some young women
Results from a large international study co-led by a VCU Massey Cancer Center physician-scientist concluded that adding ovarian suppression to adjuvant therapy (post surgery) with tamoxifen substantially reduced breast cancer recurrence in young, premenopausal women with hormone-sensitive early breast cancer who received chemotherapy because of a high risk for recurrence of their cancer.
Innovative national clinical trial offered at Massey utilizes precision medicine techniques to improve lung cancer treatment
VCU Massey Cancer Center is conducting a novel clinical trial in collaboration with the National Cancer Institute and cancer centers nationwide for patients with squamous cell lung cancer, a type of non-small cell lung cancer with different genetic changes driving the growth of cancerous cells. These genetic changes vary from person to person, and this clinical trial, named Lung-MAP, is unique in offering a targeted approach to better treat the patient.
VCU Massey Cancer Center becomes the first cancer care provider in Virginia to perform next-generation genome sequencing for precision cancer treatment
VCU Massey Cancer Center has taken precision medicine in Virginia to the next level with the introduction of advanced genomic sequencing for the treatment of cancer. Patients now have in-house access to Oncogenomics DX1, a single test that can sequence their cancer’s DNA and match them with existing or experimental therapies that target the specific molecule or gene driving their disease.